Pharsight

Xelpros generic

Xelpros is an ocular hypertension drug owned by Sun Pharm. It can be used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is an emulsion ophthalmic dosage form that contains the active ingredient latanoprost. Xelpros was first authorised for market use on 12 September, 2018 and holds total of 2 drug patents, none of which have expired.

When will Xelpros generic be available?

The patent with the latest expiration date for Xelpros is titled 'Ophthalmic composition comprising a prostaglandin' and expires on 12 September, 2029. This means that the generic version of Xelpros is expected to hit the market after this date. The release of Xelpros generic will be possible after this, opening up more affordable treatment options for patients.

Xelpros uses

The active ingredient in Xelpros, latanoprost, is effective in reducing elevated intraocular pressure. This is crucial for managing conditions such as open-angle glaucoma or ocular hypertension. The drug works by increasing the outflow of aqueous humor, the fluid in the eye, thereby reducing the pressure.

Xelpros patent expiration

Xelpros holds a total of 2 drug patents, the last of which is set to expire on 12 September, 2029. Once this patent titled 'Ophthalmic composition comprising a prostaglandin' expires, generic versions of Xelpros can potentially be released. Below are the details of the patent:

Litigations filed on Xelpros

Xelpros dosage

Want to ask something?